Prevention, treatment and potential mechanism of herbal medicine for Corona viruses: A review

References

• China National Health Commission. Diagnosis and treatment of pneumonitis caused by new coronavirus (trial version 7). In.: Beijing China National Health;2020. http://www.nhc.gov.cn/jkj/s3577/202009/318683cbfaee4191aee29cd774b19d8d.shtml
   Google Scholar
• Zu ZY, Jiang MD, Xu PP, et al. Coronavirus disease 2019 (COVID-19): a perspective from China. Radiology. 2020;296(2):E15–E25. DOI:10.1148/radiol.2020200490.
   PubMed Web of Science ®Google Scholar
• Dong Y, Mo X, Hu Y, et al. Epidemiology of COVID-19 among children in China. Pediatrics. 2020;145(6). DOI:10.1542/peds.2020-0702.
   PubMed Web of Science ®Google Scholar
• Liu Y, Eggo RM, Kucharski AJ. Secondary attack rate and superspreading events for SARS-CoV-2. Lancet. 2020;395(10227):e47.
   PubMed Web of Science ®Google Scholar
• Lu X, Zhang L, Du H, et al. SARS-CoV-2 infection in children. New Engl J Med. 2020;382(17):1663–1665. DOI:10.1056/NEJMc2005073.
   PubMed Web of Science ®Google Scholar
• Ibarrondo FJ, Fulcher JA, Goodman-Meza D, et al. Rapid decay of Anti-SARS-CoV-2 antibodies in persons with mild Covid-19. N Engl J Med. 2020;383(11):1085–1087. DOI:10.1056/NEJMc2025179.
   PubMed Web of Science ®Google Scholar
• Zhu FC, Guan XH, Li YH, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2020;396(10249):479–488. DOI:10.1016/S0140-6736(20)31605-6.
   PubMed Web of Science ®Google Scholar
• Dagotto G, Yu J, Barouch DH. Approaches and Challenges in SARS-CoV-2 vaccine development. Cell Host Microbe. 2020;28(3):364–370.
   PubMed Web of Science ®Google Scholar
• Susskind D, Vines D. The economics of the COVID-19 pandemic: an assessment. Oxford Rev Econ Pol. 2020;36(Supplement_1):S1–S13.10.1093/oxrep/graa036
   Web of Science ®Google Scholar
• Jin YH, Cai L, Cheng ZS, et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Mil Med Res. 2020;7(1):4. DOI:10.1186/s40779-020-0233-6.
   PubMed Web of Science ®Google Scholar
• Han YY, Zhao MR, and Shi Y, et al. Application of integrative medicine protocols on treatment of coronavirus disease 2019. Chin Tradit Herb Drugs. 2020;2020:2–18.
   Google Scholar
• China National Health Commission. Diagnosis and treatment of pneumonitis caused by new coronavirus (trial version 6). In.; 2020.
   Google Scholar
• Xiao M, Tian J, Zhou Y, et al. Efficacy of Huoxiang Zhengqi dropping pills and Lianhua Qingwen granules in treatment of COVID-19: a randomized controlled trial. Pharmacol Res. 2020;161:105126.
   PubMed Web of Science ®Google Scholar
• Province S. Clinical features and treatment of COVID‐19 patients in northeast Chongqing.
   Google Scholar
• Hung I, To K, Lee CK, et al. Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection. Chest. 2013;144(2):464–473. DOI:10.1378/chest.12-2907.
   PubMed Web of Science ®Google Scholar
• Zhu YL, Yang BB, Wu F. Understanding of COVID-19 in children from different perspectives of traditional Chinese medicine and western medicine. Chinese Traditional and Herbal Drugs. 2020. 51(4)
   Google Scholar
• Ni L, Zhou L, Zhou M, et al. Combination of western medicine and Chinese traditional patent medicine in treating a family case of COVID-19. Front Med. 2020;14(2):210–214. DOI:10.1007/s11684-020-0757-x.
   PubMed Web of Science ®Google Scholar
• Chan KW, Wong VT, Tang SCW. COVID-19: An update on the epidemiological, clinical, preventive and therapeutic evidence and guidelines of integrative Chinese–Western medicine for the management of 2019 novel coronavirus disease. Am J Chin Med. 2020;48(3):737–762.
   PubMed Web of Science ®Google Scholar
• Mohamad Hesam ShahrajabianMohamad Hesam Shahrajabian Biotechnology Research Institute CAOA. A review of ginseng species in different regions as a multipurpose herb in traditional Chinese medicine, modern herbology and pharmacological science. J Med Plants Res. 2019;10(13):213–226.
   Google Scholar
• Sun W, Shahrajabian MH, Cheng Q. Anise (Pimpinella anisum L), a dominant spice and traditional medicinal herb for both food and medicinal purposes. Cogent Biology. 2019;5(1):1673688.10.1080/23312025.2019.1673688
   Web of Science ®Google Scholar
• Xia S, Zhong Z, and Gao B, et al. The important herbal pair for the treatment of COVID-19 and its possible mechanisms. Chin Med. 2021;16(1): 1–16
   PubMed Web of Science ®Google Scholar
• Chia WY, Kok H, Chew KW, et al. Can algae contribute to the war with Covid-19?. Bioengineered. 2021;12(1):1226–1237. DOI:10.1080/21655979.2021.1910432.
   PubMed Web of Science ®Google Scholar
• Peter AP, Wayne CK, Show PL, et al. Potential pathway that could treat Coronaviruses (COVID-19). Current Biochemical Engineering. 2020;6(1):3–4. DOI:10.2174/2212711906999200228100507
   Google Scholar
• Yuan H, Ma Q, Ye L, et al. The traditional medicine and modern medicine from natural products. Molecules. 2016;21(5):559. DOI:10.3390/molecules21050559.
   PubMed Web of Science ®Google Scholar
• Tong T, Wu YQ, Ni WJ, et al. The potential insights of traditional Chinese medicine on treatment of COVID-19. Chin Med. 2020;15(1):51. DOI:10.1186/s13020-020-00326-w.
   PubMed Web of Science ®Google Scholar
• Jiang W. Therapeutic wisdom in traditional Chinese medicine: a perspective from modern science. Trends Pharmacol Sci. 2005;26(11):558–563.
   PubMed Web of Science ®Google Scholar
• Miao Q, Cong XD, Wang B, et al. Understanding and thinking of novel coronavirus pneumonia in traditional Chinese medicine. J Trad Chin Med. 2020;61. 286–288.
   Google Scholar
• Ang L, Lee HW, Choi JY, et al. Herbal medicine and pattern identification for treating COVID-19: a rapid review of guidelines. Integr Med Res. 2020;9(2):100407. DOI:10.1016/j.imr.2020.100407.
   PubMed Web of Science ®Google Scholar
• Lau TF, Leung PC, Wong EL, et al. Using herbal medicine as a means of prevention experience during the SARS crisis. Am J Chin Med. 2005;33(3):345–356. DOI:10.1142/S0192415X05002965.
   PubMed Web of Science ®Google Scholar
• Needham J, Gwei-djen L. Hygiene and preventive medicine in ancient China. J Hist Med Allied Sci. 1962;17(4):429–478.
   PubMedGoogle Scholar
• Luo H, Tang QL, Shang YX, et al. Can Chinese medicine be used for prevention of Corona virus disease 2019 (COVID-19)? A review of historical classics, research evidence and current prevention programs. Chin J Integr Med. 2020;26(4):243–250. DOI:10.1007/s11655-020-3192-6.
   PubMed Web of Science ®Google Scholar
• Du CY, Zheng KY, Bi CW, et al. Yu Ping Feng San, an Ancient Chinese herbal decoction, induces gene expression of anti-viral proteins and inhibits neuraminidase activity. Phytother Res. 2015;29(5):656–661. DOI:10.1002/ptr.5290.
   PubMed Web of Science ®Google Scholar
• Hoever G, Baltina L, Michaelis M, et al. Antiviral activity of glycyrrhizic acid derivatives against SARS-coronavirus. J Med Chem. 2005;48(4):1256–1259. DOI:10.1021/jm0493008.
   PubMed Web of Science ®Google Scholar
• Wang C, Cao B, Liu QQ, et al. Oseltamivir compared with the Chinese traditional therapy maxingshigan-yinqiaosan in the treatment of H1N1 influenza: a randomized trial. Ann Intern Med. 2011;155(4):217–225. DOI:10.7326/0003-4819-155-4-201108160-00005
   PubMed Web of Science ®Google Scholar
• Pu J, Mei H, Lei L, et al. Knowledge of medical professionals, their practices, and their attitudes toward traditional Chinese medicine for the prevention and treatment of coronavirus disease 2019: a survey in Sichuan, China. Plos One. 2021;16(3):e234855. DOI:10.1371/journal.pone.0234855.
   Web of Science ®Google Scholar
• Ang L, Lee HW, Choi JY, et al. Herbal medicine and pattern identification for treating COVID-19: a rapid review of guidelines. Integr Med Res. 2020;9(2):100407.
   PubMed Web of Science ®Google Scholar
• Lee B, Lee JA, Kim K, et al. A consensus guideline of herbal medicine for coronavirus disease 2019. Integr Med Res. 2020;9(3):100470. DOI:10.1016/j.imr.2020.100470.
   PubMed Web of Science ®Google Scholar
• Kim D, Chu H, Min BK, et al. Telemedicine center of Korean medicine for treating patients with COVID-19: a retrospective analysis. Integr Med Res. 2020;9(3):100492. DOI:10.1016/j.imr.2020.100492.
   PubMed Web of Science ®Google Scholar
• Takayama S, Arita R, Ono R, et al. Treatment of COVID-19-related olfactory disorder promoted by kakkontokasenkyushin’i: a case series. Tohoku J Exp Med. 2021;254(2):71–80. DOI:10.1620/tjem.254.71.
   PubMed Web of Science ®Google Scholar
• Takayama S, Namiki T, Ito T, et al. A multi-center, randomized controlled trial by the integrative management in Japan for epidemic disease (IMJEDI study-RCT) on the use of Kampo medicine, kakkonto with shosaikotokakikyosekko, in mild-to-moderate COVID-19 patients for symptomatic relief and prevention of severe stage: a structured summary of a study protocol for a randomized controlled trial. Trials. 2020;21(1):1–3. DOI:10.1186/s13063-019-3906-2.
   PubMed Web of Science ®Google Scholar
• Aomatsu N, Shigemitsu K, Nakagawa H, et al. Efficacy of Ninjin’yoeito in treating severe coronavirus disease 2019 in patients in an intensive care unit. Neuropeptides. 2021;90:102201.
   PubMed Web of Science ®Google Scholar
• Kuchta K, Cameron S, Lee M, et al. Which East Asian herbal medicines can decrease viral infections?. Phytochem Rev 2021 1–19 10.1007/s11101-021-09756-2
   Web of Science ®Google Scholar
• AlNajrany SM, Asiri Y, Sales I, et al. The commonly utilized natural products during the COVID-19 pandemic in Saudi Arabia: a cross-sectional online survey. Int J Environ Res Public Health. 2021;18(9):4688. DOI:10.3390/ijerph18094688.
   PubMed Web of Science ®Google Scholar
• ALkharashi NA. The consumption of nutritional supplements and herbal products for the prevention and treatment of COVID-19 infection among the Saudi population in riyadh. Clinical Nutrition Open Science. 2021;39:11–20. 10.1016/j.nutos.2021.09.001
   PubMedGoogle Scholar
• Koshak AE, Koshak EA, Mobeireek AF, et al. Nigella sativa for the treatment of COVID-19: an open-label randomized controlled clinical trial. Complement Ther Med. 2021;61:102769.
   PubMed Web of Science ®Google Scholar
• Ahmad A, Husain A, Mujeeb M, et al. A review on therapeutic potential of Nigella sativa: a miracle herb. Asian Pac J Tropical Biomedicine. 2013;3(5):337–352. DOI:10.1016/S2221-1691(13)60075-1.
   PubMedGoogle Scholar
• Rahman MT. Potential benefits of combination of Nigella sativa and Zn supplements to treat COVID-19. J Herbs Med. 2020;23:100382.
   PubMed Web of Science ®Google Scholar
• Bouchentouf S, Missoum N. Identification of Compounds from Nigella Sativa as new potential inhibitors of 2019 novel Coronasvirus (Covid-19): molecular docking study. 2020.
   Google Scholar
• Ahmed I, Hasan M, Akter R, et al. Behavioral preventive measures and the use of medicines and herbal products among the public in response to Covid-19 in Bangladesh: a cross-sectional study. Plos One. 2020;15(12):e243706. DOI:10.1371/journal.pone.0243706.
   Web of Science ®Google Scholar
• Saraswat J, Singh P, Patel R. A computational approach for the screening of potential antiviral compounds against SARS-CoV-2 protease: ionic liquid vs herbal and natural compounds. J Mol Liq. 2021;326:115298.
   PubMed Web of Science ®Google Scholar
• Charan J, Bhardwaj P, Dutta S, et al. Use of complementary and alternative medicine (CAM) and home remedies by COVID-19 patients: a telephonic survey. Indian J Clin Biochem. 2021;36(1):108–111. DOI:10.1007/s12291-020-00931-4.
   PubMed Web of Science ®Google Scholar
• Banerjee S, Kar A, Mukherjee PK, et al. Immunoprotective potential of ayurvedic herb kalmegh (Andrographis paniculata) against respiratory viral infections–LC–MS/MS and network pharmacology analysis. Phytochem Analysis. 2021;32(4):629–639. DOI:10.1002/pca.3011
   PubMed Web of Science ®Google Scholar
• Balkrishna A, Verma S, Solleti SK, et al. Calcio-herbal medicine Divya-Swasari-Vati ameliorates SARS-CoV-2 spike protein-induced pathological features and inflammation in humanized zebrafish model by moderating IL-6 and TNF-α cytokines. J Inflamm Res. 2020;13:1219.
   PubMed Web of Science ®Google Scholar
• Natarajan S, Anbarasi C, Sathiyarajeswaran P, et al. Kabasura Kudineer (KSK), a poly-herbal Siddha medicine, reduced SARS-CoV-2 viral load in asymptomatic COVID-19 individuals as compared to vitamin C and zinc supplementation: findings from a prospective, exploratory, open-labeled, comparative, randomized controlled trial, Tamil Nadu, India. Trials. 2021;22(1):1–11. DOI:10.1186/s13063-020-04976-x.
   PubMed Web of Science ®Google Scholar
• Dandara C, Dzobo K, Chirikure S. COVID-19 pandemic and Africa: from the situation in Zimbabwe to a case for precision herbal medicine. OMICS. 2021;25(4):209–212.
   PubMed Web of Science ®Google Scholar
• Nie C, Trimpert J, Moon S, et al. In vitro efficacy of artemisia extracts against SARS-CoV-2. bioRxiv. 2021.
   PubMedGoogle Scholar
• Chali BU, Melaku T, Berhanu N, et al. Traditional medicine practice in the context of COVID-19 pandemic: community claim in jimma zone, Oromia, Ethiopia. Infect Drug Resist. 2021;14:3773.
   PubMed Web of Science ®Google Scholar
• Scherrer AM, Motti R, Weckerle CS. Traditional plant use in the areas of monte vesole and ascea, cilento national park (Campania, Southern Italy). J Ethnopharmacol. 2005;97(1):129–143.
   PubMed Web of Science ®Google Scholar
• Chaachouay N, Douira A, Zidane L. COVID-19, prevention and treatment with herbal medicine in the herbal markets of salé prefecture, North-Western Morocco. Eur J Integr Med. 2021;42:101285.
   PubMed Web of Science ®Google Scholar
• Aanouz I, Belhassan A, El-Khatabi K, et al. Moroccan Medicinal plants as inhibitors against SARS-CoV-2 main protease: computational investigations. J Biomol Struct Dyn. 2021;39(8):2971–2979. DOI:10.1080/07391102.2020.1758790.
   PubMed Web of Science ®Google Scholar
• Mata R, Figueroa M, Navarrete A, et al. Chemistry and biology of selected Mexican medicinal plants. Prog Chem Org Nat Prod. 2019;108(2019):1–142. DOI:10.1007/978-3-030-01099-7_1.
   PubMedGoogle Scholar
• Rivero-Segura NA, Gomez-Verjan JC. In silico screening of natural products isolated from Mexican herbal medicines against COVID-19. Biomolecules. 2021;11(2):216.
   PubMed Web of Science ®Google Scholar
• Kim D, Lee JY, Yang JS, et al. The architecture of SARS-CoV-2 transcriptome. Cell. 2020;181(4):914–921. DOI:10.1016/j.cell.2020.04.011.
   PubMed Web of Science ®Google Scholar
• Chan JF, Kok KH, Zhu Z, et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect. 2020;9(1):221–236. DOI:10.1080/22221751.2020.1719902.
   PubMed Web of Science ®Google Scholar
• Kim JM, Chung YS, Jo HJ, et al. Identification of Coronavirus isolated from a patient in Korea with COVID-19. Osong Public Health Res Perspect. 2020;11(1):3–7. DOI:10.24171/j.phrp.2020.11.1.02.
   PubMedGoogle Scholar
• Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270–273. DOI:10.1038/s41586-020-2012-7.
   PubMed Web of Science ®Google Scholar
• Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271–280. DOI:10.1016/j.cell.2020.02.052.
   PubMed Web of Science ®Google Scholar
• Poduri R, Joshi G, Jagadeesh G. Drugs targeting various stages of the SARS-CoV-2 life cycle: exploring promising drugs for the treatment of Covid-19. Cell Signal. 2020;74:109721.
   PubMed Web of Science ®Google Scholar
• Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. DOI:10.1016/S0140-6736(20)30183-5.
   PubMed Web of Science ®Google Scholar
• Fung TS, Liao Y, Liu DX. Regulation of stress responses and translational control by Coronavirus. Viruses. 2016;8(7):184.
   PubMed Web of Science ®Google Scholar
• Xiao H, Xu LH, Yamada Y, et al. Coronavirus spike protein inhibits host cell translation by interaction with eIF3f. Plos One. 2008;3(1):e1494. DOI:10.1371/journal.pone.0001494.
   PubMed Web of Science ®Google Scholar
• Lokugamage KG, Narayanan K, Nakagawa K, et al. Middle East respiratory syndrome Coronavirus nsp1 inhibits host gene expression by selectively targeting mrnas transcribed in the nucleus while sparing mRNAs of cytoplasmic origin. J Virol. 2015;89(21):10970–10981. DOI:10.1128/JVI.01352-15.
   PubMed Web of Science ®Google Scholar
• Lokugamage KG, Narayanan K, Huang C, et al. Severe acute respiratory syndrome coronavirus protein nsp1 is a novel eukaryotic translation inhibitor that represses multiple steps of translation initiation. J Virol. 2012;86(24):13598–13608. DOI:10.1128/JVI.01958-12.
   PubMed Web of Science ®Google Scholar
• Schubert K, Karousis ED, Jomaa A, et al. SARS-CoV-2 Nsp1 binds the ribosomal mRNA channel to inhibit translation. Nat Struct Mol Biol. 2020;27(10):959–966. DOI:10.1038/s41594-020-0511-8.
   PubMed Web of Science ®Google Scholar
• Ma-Lauer Y, Carbajo-Lozoya J, Hein MY, et al. p53 down-regulates SARS coronavirus replication and is targeted by the SARS-unique domain and PLpro via E3 ubiquitin ligase RCHY1. Proc Natl Acad Sci U S A. 2016;113(35):E5192–E5201. DOI:10.1073/pnas.1603435113.
   PubMed Web of Science ®Google Scholar
• Wei J, Alfajaro MM, Hanna RE, et al. Genome-wide CRISPR screen reveals host genes that regulate SARS-CoV-2 infection. bioRxiv. 2020.
   Google Scholar
• Frieman M, Heise M, Baric R. SARS coronavirus and innate immunity. Virus Res. 2008;133(1):101–112.
   PubMed Web of Science ®Google Scholar
• Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–513. DOI:10.1016/S0140-6736(20)30211-7.
   PubMed Web of Science ®Google Scholar
• Appelberg S, Gupta S, Svensson AS, et al. Dysregulation in Akt/mTOR/HIF-1 signaling identified by proteo-transcriptomics of SARS-CoV-2 infected cells. Emerg Microbes Infect. 2020;9(1):1748–1760. DOI:10.1080/22221751.2020.1799723.
   PubMed Web of Science ®Google Scholar
• Fung TS, Liu DX. Human Coronavirus: Host-Pathogen interaction. Annu Rev Microbiol. 2019;73(1):529–557.
   PubMed Web of Science ®Google Scholar
• Min JS, Kim DE, Jin Y, et al. Kurarinone inhibits HCoV-OC43 infection by impairing the virus-induced autophagic flux in MRC-5 human lung cells. J Clin Med. 2020;9(7):2230. DOI:10.3390/jcm9072230.
   PubMed Web of Science ®Google Scholar
• He T, Qu R, Qin C, et al. Potential mechanisms of Chinese herbal medicine that implicated in the treatment of COVID-19 related renal injury. Saudi Pharm J. 2020;28(9):1138–1148. DOI:10.1016/j.jsps.2020.08.002.
   PubMed Web of Science ®Google Scholar
• Shukla R, Singh S, Singh A, et al. Two pronged approach for prevention and therapy of COVID-19 (Sars-CoV-2) by a multi-targeted herbal drug, a component of ayurvedic decoction. Eur J Integr Med. 2021;43:101268.
   PubMed Web of Science ®Google Scholar
• Roshdy WH, Rashed HA, Kandeil A, et al. EGYVIR: an immunomodulatory herbal extract with potent antiviral activity against SARS-CoV-2. Plos One. 2020;15(11):e241739. DOI:10.1371/journal.pone.0241739.
   Web of Science ®Google Scholar
• Pan B, Fang S, Zhang J, et al. Chinese herbal compounds against SARS-CoV-2: puerarin and quercetin impair the binding of viral S-protein to ACE2 receptor. Comput Struct Biotec. 2020; 18: 3518–3527. 10.1016/j.csbj.2020.11.010
   PubMed Web of Science ®Google Scholar
• Siddiqui S, Upadhyay S, Ahmad R, et al. Virtual screening of phytoconstituents from miracle herb nigella sativa targeting nucleocapsid protein and papain-like protease of SARS-CoV-2 for COVID-19 treatment. J Biomol Struct Dyn 2020 1–21 10.1080/07391102.2020.1852117
   Web of Science ®Google Scholar
• Du A, Zheng R, Disoma C, et al. Epigallocatechin-3-gallate, an active ingredient of traditional Chinese medicines, inhibits the 3CLpro activity of SARS-CoV-2. Int J Biol Macromol. 2021;176:1–12.
   PubMed Web of Science ®Google Scholar
• Lv Y, Wang S, Liang P, et al. Screening and evaluation of anti-SARS-CoV-2 components from Ephedra sinica by ACE2/CMC-HPLC-IT-TOF-MS approach. Anal Bioanal Chem. 2021;413(11):2995–3004. DOI:10.1007/s00216-021-03233-7.
   PubMed Web of Science ®Google Scholar
• Amparo TR, Seibert JB, Almeida TC, et al. In silico approach of secondary metabolites from Brazilian herbal medicines to search for potential drugs against SARS-CoV2. Phytother Res. 2021;35(8):4297–4308. DOI:10.1002/ptr.7097.
   PubMed Web of Science ®Google Scholar
• Chaturvedi M, Nagre K, Yadav JP. In silico approach for identification of natural compounds as potential COVID 19 main protease (Mpro) inhibitors. VirusDisease. 2021;1–5. DOI:10.1007/s13337-021-00701-7
   PubMedGoogle Scholar
• Tejera E, Pérez-Castillo Y, Toscano G, et al. Computational modeling predicts potential effects of the herbal infusion “horchata” against COVID-19. Food Chem. 2022;366:130589.
   PubMed Web of Science ®Google Scholar
• Gurung AB, Ali MA, and Lee J, et al. Identification of SARS-CoV-2 inhibitors from extracts of Houttuynia cordata Thunb. Saudi J Biol Sci. 2021;28(12): 7517–7527.
   PubMed Web of Science ®Google Scholar
• Cao R, Hu H, Li Y, et al. Anti-SARS-CoV-2 potential of artemisinins in vitro. Acs Infect Dis. 2020;6(9):2524–2531. DOI:10.1021/acsinfecdis.0c00522.
   PubMed Web of Science ®Google Scholar
• Mu C, Sheng Y, Wang Q, et al. Potential compound from herbal food of rhizoma polygonati for treatment of COVID-19 analyzed by network pharmacology: viral and cancer signaling mechanisms. J Funct Foods. 2021;77:104149.
   PubMed Web of Science ®Google Scholar
• Yepes-Pérez AF, Herrera-Calderon O, Quintero-Saumeth J. Uncaria tomentosa (cat’s claw): a promising herbal medicine against SARS-CoV-2/ACE-2 junction and SARS-CoV-2 spike protein based on molecular modeling. J Biomol Struct Dyn. 2020;1–17. DOI:10.1080/07391102.2020.1837676
   Web of Science ®Google Scholar
• Huynh T, Wang H, Luan B. Structure-based lead optimization of herbal medicine rutin for inhibiting SARS-CoV-2ʹs main protease. Phys Chem Chem Phys. 2020;22(43):25335–25343.
   PubMed Web of Science ®Google Scholar
• Lu X, Yujing S, Jie SU, et al. Shufeng Jiedu, a promising herbal therapy for moderate COVID-19: antiviral and anti-inflammatory properties, pathways of bioactive compounds, and a clinical real-world pragmatic study. Phytomedicine. 2021;85:153390.
   PubMed Web of Science ®Google Scholar
• Gupta S, Singh V, Varadwaj PK, et al. Secondary metabolites from spice and herbs as potential multitarget inhibitors of SARS-CoV-2 proteins. J Biomol Struct Dyn 2020 1–20 10.1080/07391102.2020.1837679
   PubMed Web of Science ®Google Scholar
• Balkrishna A, Haldar S, Singh H, et al. Coronil, a tri-herbal formulation, attenuates spike-protein-mediated SARS-CoV-2 viral entry into human alveolar epithelial cells and pro-inflammatory cytokines production by inhibiting spike protein-ACE-2 interaction. J Inflamm Res. 2021;14:869.
   PubMed Web of Science ®Google Scholar
• Wen CC, Kuo YH, Jan JT, et al. Specific plant terpenoids and lignoids possess potent antiviral activities against severe acute respiratory syndrome coronavirus. J Med Chem. 2007;50(17):4087–4095. DOI:10.1021/jm070295s.
   PubMed Web of Science ®Google Scholar
• Ryu YB, Park SJ, Kim YM, et al. SARS-CoV 3CLpro inhibitory effects of quinone-methide triterpenes from Tripterygium regelii. Bioorg Med Chem Lett. 2010;20(6):1873–1876. DOI:10.1016/j.bmcl.2010.01.152.
   PubMed Web of Science ®Google Scholar
• Park JY, Kim JH, Kim YM, et al. Tanshinones as selective and slow-binding inhibitors for SARS-CoV cysteine proteases. Bioorg Med Chem. 2012;20(19):5928–5935. DOI:10.1016/j.bmc.2012.07.038.
   PubMed Web of Science ®Google Scholar
• Park JY, Kim JH, Kwon JM, et al. Dieckol, a SARS-CoV 3CL(pro) inhibitor, isolated from the edible brown algae Ecklonia cava. Bioorg Med Chem. 2013;21(13):3730–3737. DOI:10.1016/j.bmc.2013.04.026.
   PubMed Web of Science ®Google Scholar
• Song YH, Kim DW, Curtis-Long MJ, et al. Papain-like protease (PLpro) inhibitory effects of cinnamic amides from Tribulus terrestris fruits. Biol Pharm Bull. 2014;37(6):1021–1028. DOI:10.1248/bpb.b14-00026.
   PubMed Web of Science ®Google Scholar
• Park JY, Ko JA, Kim DW, et al. Chalcones isolated from Angelica keiskei inhibit cysteine proteases of SARS-CoV. J Enzyme Inhib Med Chem. 2016;31(1):23–30. DOI:10.3109/14756366.2014.1003215.
   PubMed Web of Science ®Google Scholar
• Liu L-S et al The Effects and Mechanism of Yinqiao Powder on Upper Respiratory Tract Infection . International Journal of Biotechnology for Wellness Industries. 2(4). 57–60
   Google Scholar
• Ding Y, Zeng L, Li R, et al. The Chinese prescription lianhuaqingwen capsule exerts anti-influenza activity through the inhibition of viral propagation and impacts immune function. BMC Complement Altern Med. 2017;17(1):130. DOI:10.1186/s12906-017-1585-7.
   PubMed Web of Science ®Google Scholar
• Gao J, Li J, Shao X, et al. Antiinflammatory and immunoregulatory effects of total glucosides of Yupingfeng powder. Chin Med J (Engl). 2009;122(14):1636–1641.
   PubMed Web of Science ®Google Scholar
• Su H, Yao S, Zhao W, et al. Anti-SARS-CoV-2 activities in vitro of Shuanghuanglian preparations and bioactive ingredients. Acta Pharmacol Sin. 2020;41(9):1167–1177. DOI:10.1038/s41401-020-0483-6.
   PubMed Web of Science ®Google Scholar
• Zeng M, Li L, Wu Z. Traditional Chinese medicine Lianhua Qingwen treating Corona virus disease 2019 (COVID-19): meta-analysis of randomized controlled trials. Plos One. 2020;15(9):e238828.
   Web of Science ®Google Scholar
• Cheng Dezhong LY. Clinical effectiveness and case analysis in 54 NCP patients treated with Lianhuaqingwen Granules. World Chin Med. 2020;15(15):150–154.
   Google Scholar
• Lv R et al. Clinical observation on 63 cases of suspected cases of new Coronavirus pneumonia treated by Chinese medicine lianhua qingwen. J Tradit Chin Med. 2020.
   Google Scholar
• Yao K et al. Retrospective clinical analysis on treatment of novel coronavirus-infected pneumonia with traditional Chinese medicine lianhua qingwen. Chin J Exp Tradit Med Formul. 2020;
   PubMedGoogle Scholar
• Li H, Yang L, Liu FF, et al. Overview of therapeutic drug research for COVID-19 in China. Acta Pharmacol Sin. 2020;41(9):1133–1140. DOI:10.1038/s41401-020-0438-y.
   PubMed Web of Science ®Google Scholar
• Li T, Lu H, Zhang W. Clinical observation and management of COVID-19 patients. Emerg Microbes Infect. 2020;9(1):687–690.
   PubMed Web of Science ®Google Scholar
• Hu K, Guan WJ, Bi Y, et al. Efficacy and safety of Lianhuaqingwen capsules, a repurposed Chinese herb, in patients with coronavirus disease 2019: a multicenter, prospective, randomized controlled trial. Phytomedicine. 2020;85:153242.
   PubMed Web of Science ®Google Scholar
• Runfeng L, Yunlong H, Jicheng H, et al. Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2). Pharmacol Res. 2020;156:104761.
   PubMed Web of Science ®Google Scholar
• Chinese traditional and herbal drugs. 2020.
   Google Scholar
• Liu J, Jiang Y, Liu Y, et al. Yindan Jiedu granules, a traditional Chinese medicinal formulation, as a potential treatment for Coronavirus disease 2019. Front Pharmacol. 2021;11:2449.
   Web of Science ®Google Scholar
• Feng J, Fang B, and Zhou D, et al. Clinical effect of traditional Chinese Medicine Shenhuang Granule in Critically Ill Patients with COVID-19: a Single-Centered, Retrospective, Observational Study. J Microbiol Biotechnol. 2021 31 3 380–386 ;
   PubMed Web of Science ®Google Scholar
• Hetrick B, Yu D, Olanrewaju AA, et al. A traditional medicine, respiratory detox shot (RDS), inhibits the infection of SARS-CoV, SARS-CoV-2, and the influenza A virus in vitro. Cell Biosci. 2021;11(1):1–12.
   PubMed Web of Science ®Google Scholar
• Wang Y, Liu Y, Lv Q, et al. Effect and safety of Chinese herbal medicine granules in patients with severe coronavirus disease 2019 in Wuhan, China: a retrospective, single-center study with propensity score matching. Phytomedicine. 2020;85:153404.
   PubMed Web of Science ®Google Scholar
• Shi N, Guo L, Liu B, et al. Efficacy and safety of Chinese herbal medicine versus lopinavir-ritonavir in adult patients with coronavirus disease 2019: a non-randomized controlled trial. Phytomedicine. 2021;81:153367.
   PubMed Web of Science ®Google Scholar
• Liang S, Zhang Y, Shen C, et al. Chinese herbal medicine used with or without conventional Western therapy for COVID-19: an evidence review of clinical studies. Front Pharmacol. 2021;11:2321.
   Web of Science ®Google Scholar
• Liu L, Shi F, and Tu P, et al. Arbidol combined with the Chinese medicine Lianhuaqingwen capsule versus arbidol alone in the treatment of COVID-19. Medicine (Baltimore). 2021;100(4):e24475.
   PubMed Web of Science ®Google Scholar
• Jin W, Qiao L, Li Y. Effects of shen-fu injection on lipopolysaccharide-induced NF-κB activity and cytokine release in rat alveolar macrophages. Acta Medicinae Universitatis Scientiae Et Technologiae Huazhong. 2009.
   Google Scholar
• Xiu-Juan C, Shuai Z, and Yi-Ping J, et al. Mechanism of reduning injection on anti-acute lung injury in rats based on cytokine storm. Acta Pharmaceutica Sinica. 2015;46(2): 236–239
   Google Scholar
• Han L, Zhang Y, and Li H, et al. Network pharmacologic molecular mechanism of shenmai injection in treatment of COVID-19 combined with coronary heart disease. Acta Pharmaceutica Sinica. 2020;51(9): 2334–2344
   Google Scholar
• Ma Q, Xie Y, Wang Z, et al. Efficacy and safety of reDuNing injection as a treatment for COVID-19 and its inhibitory effect against SARS-CoV-2. J Ethnopharmacol. 2021;279:114367.
   PubMed Web of Science ®Google Scholar
• Zhang XY, Lv L, Zhou YL, et al. Efficacy and safety of Xiyanping injection in the treatment of COVID-19: a multicenter, prospective, open-label and randomized controlled trial. Phytother Res. 2021;35(8):4401–4410. DOI:10.1002/ptr.7141.
   PubMed Web of Science ®Google Scholar
• de Wilde AH, Snijder EJ, Kikkert M, et al. Host factors in Coronavirus replication. Curr Top Microbiol Immunol. 2018;419:1–42.
   PubMed Web of Science ®Google Scholar
• Fehr AR, Perlman S. Coronaviruses: an overview of their replication and pathogenesis. Methods Mol Biol. 2015;1282:1–23.
   PubMedGoogle Scholar
• Báez-Santos YM, St JS, Mesecar AD. The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds. Antiviral Res. 2015;115:21–38.
   PubMed Web of Science ®Google Scholar
• Morse JS, Lalonde T, Xu S, et al. Learning from the past: possible urgent prevention and treatment options for severe acute respiratory infections caused by 2019-nCoV. Chembiochem. 2020;21(5):730–738. DOI:10.1002/cbic.202000047.
   PubMed Web of Science ®Google Scholar
• Wu, H et al Preliminary exploration of the mechanism of Qingfei Paidu decoction against novel coronavirus pneumonia based on network pharmacology. Acta Pharmaceutica Sinica. 2020. 513:2317–2325
   Google Scholar
• Meng XY, Zhang HX, Mezei M, et al. Molecular docking: a powerful approach for structure-based drug discovery. Curr Comput Aided Drug Des. 2011;7(2):146–157. DOI:10.2174/157340911795677602.
   PubMed Web of Science ®Google Scholar
• Nguyen TT, Woo HJ, Kang HK, et al. Flavonoid-mediated inhibition of SARS coronavirus 3C-like protease expressed in Pichia pastoris. Biotechnol Lett. 2012;34(5):831–838. DOI:10.1007/s10529-011-0845-8.
   PubMed Web of Science ®Google Scholar
• Enmozhi SK, Raja K, Sebastine I, et al. Andrographolide as a potential inhibitor of SARS-CoV-2 main protease: an in silico approach. J Biomol Struct Dyn 2020 1–7 10.1080/07391102.2020.1760136
   Google Scholar
• Cinatl J, Morgenstern B, Bauer G, et al. Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus. Lancet. 2003;361(9374):2045–2046. DOI:10.1016/S0140-6736(03)13615-X.
   PubMed Web of Science ®Google Scholar
• Su H, Yao S, Zhao W, et al. Discovery of baicalin and baicalein as novel, natural product inhibitors of SARS-CoV-2 3CL protease in vitro. bioRxiv. 2020;2020–2024.
   Google Scholar
• Yu Y, Zhang Y, Wang S, et al. Inhibition effects of patchouli alcohol against influenza a virus through targeting cellular PI3K/Akt and ERK/MAPK signaling pathways. Virol J. 2019;16(1):163. DOI:10.1186/s12985-019-1266-x.
   PubMed Web of Science ®Google Scholar
• Ryu YB, Jeong HJ, Kim JH, et al. Biflavonoids from Torreya nucifera displaying SARS-CoV 3CL(pro) inhibition. Bioorg Med Chem. 2010;18(22):7940–7947. DOI:10.1016/j.bmc.2010.09.035.
   PubMed Web of Science ®Google Scholar
• Yu S, Wang J, Shen H. Network pharmacology-based analysis of the role of traditional Chinese herbal medicines in the treatment of COVID-19. Ann Palliat Med. 2020;9(2):437–446.
   PubMed Web of Science ®Google Scholar
• Ling X, Tao J, and Sun X, et al. Exploring material basis and mechanism of lianhua qingwen prescription against coronavirus based on network pharmacology. Acta Pharmaceutica Sinica. 2020;51(7): 1723–1730
   Google Scholar
• Chen, H , Du, Q Potential natural compounds for preventing SARS-CoV-2 (2019-nCoV) infection. Preprints. 2020.
   Google Scholar
• Wu, H et al Preliminary exploration of the mechanism of Qingfei Paidu decoction against novel coronavirus pneumonia based on network pharmacology and molecular docking technolog. Acta Pharmaceutica Sinica. 2020;55(3):374–383.
   Google Scholar
• Tao Q, Du J, Li X, et al. Network pharmacology and molecular docking analysis on molecular targets and mechanisms of Huashi Baidu formula in the treatment of COVID-19. Drug Dev Ind Pharm. 2020;46(8):1345–1353. DOI:10.1080/03639045.2020.1788070.
   PubMed Web of Science ®Google Scholar
• Jimilihan SMY. Study on the active components in the adjuvant treatment of novel coronavirus pneumonia (COVID-19) with jinhua qinggan granules based on network pharmacology and molecular docking. Journal of Chinese Medicinal Materials. 2020;3:1–10.
   Google Scholar
• Fu FZWY S. Based on network pharmacology and high-throughput molecular docking to study the potential molecular mechanism of active compounds tthat bind SARS-Cov-2 specific target protein in Jinhua Qinggan granules to interfere with CovID-19. Modernization of Traditional Chinese Medicine and Materia Materia-World Science and Technology. 2020;1:1–10.
   Google Scholar
• Shahrajabian MH, Sun W, Soleymani A, et al. Traditional herbal medicines to overcome stress, anxiety and improve mental health in outbreaks of human coronaviruses. Phytother Res. 2021;35(3):1237–1247. DOI:10.1002/ptr.6888.
   PubMed Web of Science ®Google Scholar
• Pan F, Ye T, Sun P, et al. Time course of lung changes at chest CT during recovery from Coronavirus disease 2019 (COVID-19). Radiology. 2020;295(3):715–721. DOI:10.1148/radiol.2020200370.
   PubMed Web of Science ®Google Scholar
• Hadjadj J, Yatim N, Barnabei L, et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science. 2020;369(6504):718–724. DOI:10.1126/science.abc6027.
   PubMed Web of Science ®Google Scholar
• Yang G, Tan Z, Zhou L, et al. Effects of Angiotensin II receptor blockers and ACE (Angiotensin-Converting Enzyme) inhibitors on virus infection, inflammatory status, and clinical outcomes in patients with COVID-19 and hypertension: a single-center retrospective study. Hypertension. 2020;76(1):51–58. DOI:10.1161/HYPERTENSIONAHA.120.15143.
   PubMed Web of Science ®Google Scholar
• Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033–1034. DOI:10.1016/S0140-6736(20)30628-0.
   PubMed Web of Science ®Google Scholar
• Zhang DH, Wu KL, Zhang X, et al. In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus. J Integr Med. 2020;18(2):152–158. DOI:10.1016/j.joim.2020.02.005.
   PubMed Web of Science ®Google Scholar
• Li L, Zhang Z, Zhou W, et al. Lianhua Qingwen prescription for Coronavirus disease 2019 (COVID-19) treatment: advances and prospects. Biomed Pharmacother. 2020;130:110641.
   PubMed Web of Science ®Google Scholar
• Zhao J, Tian S, and Yang J, et al. Investigating mechanism of Qing-Fei-Pai-Du-Tang for treatment of COVID-19 by network pharmacology. Chin. Trad. Herbal Drugs. 2020;4(51):829–835.
   Google Scholar
• Chen J, Wang Y, Gao Y, et al. Protection against COVID-19 injury by qingfei paidu decoction via anti-viral, anti-inflammatory activity and metabolic programming. Biomed Pharmacother. 2020;129:110281.
   PubMed Web of Science ®Google Scholar
• Huang YF, Bai C, He F, et al. Review on the potential action mechanisms of Chinese medicines in treating Coronavirus disease 2019 (COVID-19). Pharmacol Res. 2020;158:104939.
   PubMed Web of Science ®Google Scholar
• Liu Y, Wei P, and Qiu Z. Study on mechanism of Shufeng Jiedu granules in treating novel coronavirus pneumonia based on network pharmacology. 2019 International Conference on Biotechnology and Bioengineering(9th ICBB) . 2020-01-01 2020: AIP Publishing LLC; 2020. 20013
   Google Scholar
• Ren Y, Yao MC, Huo XQ, et al. Study on treatment of “cytokine storm” by anti-2019-nCoV prescriptions based on arachidonic acid metabolic pathway. Zhongguo Zhong Yao Za Zhi. 2020;45(6):1225–1231. DOI:10.19540/j.cnki.cjcmm.20200224.405.
   PubMedGoogle Scholar
• Cao C, Cui Y, Chu Y, et al. Investigation on mechanism and active components of shufeng jiedu capsule in treatment of COVID-19 based on network pharmacology and molecular docking. Chin. Trad. Herbal Drugs. 2020;51(9): 2283–2296
   Google Scholar
• Shen FFZY. The potential targets and mechanisms of shufeng jiedu capsule for novel coronavirus pneumonia (COVID-19) based on network pharmacology and molecular docking. Guiding J Tradit Chin Med Pharm. 2020;5(26):8–15.
   Google Scholar
• Zhang T. Basic study on treatment of COVID-19 with shufeng jiedu capsule and research and development ideas of new Chinese materia medica against COVID-19. Chin. Trad. Herbal Drugs. 2020;9(51):2273–2282.
   Google Scholar
• Yang R, Liu H, Bai C, et al. Chemical composition and pharmacological mechanism of Qingfei Paidu decoction and Ma Xing Shi Gan decoction against Coronavirus disease 2019 (COVID-19): in silico and experimental study. Pharmacol Res. 2020;157:104820.
   PubMed Web of Science ®Google Scholar
• Ma Q, Pan W, Li R, et al. Liu Shen capsule shows antiviral and anti-inflammatory abilities against novel coronavirus SARS-CoV-2 via suppression of NF-κB signaling pathway. Pharmacol Res. 2020;158:104850.
   PubMed Web of Science ®Google Scholar
• Xiong W, Wang G, Du J, et al. Efficacy of herbal medicine (Xuanfei Baidu decoction) combined with conventional drug in treating COVID-19: a pilot randomized clinical trial. Integr Med Res. 2020;9(3):100489. DOI:10.1016/j.imr.2020.100489.
   PubMed Web of Science ®Google Scholar
• Zhang X, Xue Y, Chen X, et al. Effects of tanreqing capsule on the negative conversion time of nucleic acid in patients with COVID-19: a retrospective cohort study. J Integr Med. 2021;19(1):36–41. DOI:10.1016/j.joim.2020.10.002.
   PubMed Web of Science ®Google Scholar
• Cui Y, Xin H, Tao Y, et al. Arenaria kansuensis attenuates pulmonary fibrosis in mice via the activation of Nrf2 pathway and the inhibition of NF‐kB/TGF‐beta1/Smad2/3 pathway. Phytother Res. 2021;35(2):974–986. DOI:10.1002/ptr.6857.
   PubMed Web of Science ®Google Scholar
• De Jin XA, Zhang Y, and Zhao S, et al. Potential mechanism prediction of herbal medicine for pulmonary fibrosis associated with SARS-CoV-2 infection based on network analysis and molecular docking. Front Pharmacol. 2021;12:602218. doi:10.3389/fphar.2021.602218.
   PubMed Web of Science ®Google Scholar
• Yang Y. Use of herbal drugs to treat COVID-19 should be with caution. Lancet. 2020;395(10238):1689–1690.
   PubMed Web of Science ®Google Scholar